Related Experiment Video
Updated: Aug 14, 2026
Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation
Published on: May 16, 2016
Human endotoxemia: a model for mechanistic insight and therapeutic targeting
1UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08903-0019, USA. lowrysf@umdnj.edu
Abstract:
The diversity of phenotypic manifestations, comorbidities, and therapeutic algorithms in patients with severe inflammation have confounded efforts to translate mechanistic insights from the bench top to the bedside. This dilemma has negatively impacted upon many therapeutic interventions that exhibited seemingly well-reasoned preclinical portfolios. Prudence urges the assessment of potent immunoregulatory therapies, wherever possible, in models that replicate the clinical phenotype absent overt manifestations of genetically or environmentally modified processes. The healthy human model of endotoxin administration (systemic or endobronchial) provides such an opportunity and has been used to great advantage for gaining insight into mechanisms of disease and for determination of therapeutic signal strength. When thoughtfully interpreted, the model may provide proof of principle as well as lessen the unpredictability of clinical responses. Although the broad characteristics of this model are well described in the literature, it is recognized that this model does not fully replicate the magnitude of initial inflammatory stress nor the latent spectrum of inflammation/sepsis-inducible organ system pathologies. Nevertheless, the similarities between the early, transient clinical phenotype, inducible physiochemical change, and biochemical pathway activation of this model to the early hyperdynamic phase of resuscitated injury and infection are striking. Rational testing of a therapeutic mechanism requires a quantifiable and reproducibly altered marker of the hypothetical mechanism. Given the modest nature of endotoxin induced insult, interventions that demonstrate target specific efficacy in conjunction with attenuated phenotype responses are more likely to exhibit efficacy within lower risk patient populations. By contrast, the model cannot predict clinical efficacy among higher risk patients nor in those who have endured extended periods of inflammatory stress.
Insights
The endotoxin-induced inflammation model in healthy humans offers valuable insights into severe inflammation mechanisms and therapeutic potential. This model aids in predicting drug efficacy, particularly for less severe inflammatory conditions.
Area of Science:
- Immunology
- Pharmacology
- Clinical Medicine
Background:
- Translating preclinical findings in severe inflammation to clinical practice is challenging due to diverse patient phenotypes and comorbidities.
- Preclinical models often fail to fully replicate the complexity of human inflammatory diseases, impacting therapeutic intervention success.
- Potent immunoregulatory therapies require assessment in models that mimic clinical phenotypes without genetic or environmental modifications.
Purpose of the Study:
- To evaluate the utility of a healthy human endotoxin administration model for understanding severe inflammation.
- To assess the model's capability in predicting the efficacy of therapeutic interventions.
- To identify the strengths and limitations of this model in preclinical drug development.
Main Methods:
- Utilizing systemic or endobronchial endotoxin administration in healthy human volunteers to induce a controlled inflammatory response.
- Analyzing the early, transient clinical phenotype, physiochemical changes, and biochemical pathway activation.
- Comparing the model's inflammatory profile to the early hyperdynamic phase of resuscitated injury and infection.
Main Results:
- The endotoxin model provides valuable insights into disease mechanisms and therapeutic signal strength, aiding proof of principle.
- Similarities were observed in early clinical phenotype, physiochemical changes, and biochemical activation between the model and early-phase human inflammation.
- The model is best suited for identifying interventions with target-specific efficacy and attenuated responses, likely predicting success in lower-risk patients.
Conclusions:
- The healthy human endotoxin model is a valuable tool for studying inflammation and testing immunoregulatory therapies.
- While not replicating the full severity or pathology of sepsis, the model effectively mimics early inflammatory phases.
- The model's predictive value is highest for interventions demonstrating efficacy in less severe inflammatory states and lower-risk patient populations.
